Table 2.
Univariate and multivariate analyses of factors associated with overall survival and progress-free interval in the TCGA CRC cohort.
| Univariate analysisb | Multivariate analysisb | |||
|---|---|---|---|---|
| HR (95% CI) | P valuea | HR (95% CI) | P valuea | |
| TCGA CRC/OS (n = 359) | ||||
| Gender (male vs. female) | 1.143 (0.83-1.574) | 0.412 | ||
| Age (≤65 vs. >65) | 0.586 (0.415-0.827) | 0.002 | 0.522 (0.369-0.739) | <0.001 |
| Stage (III-IV vs. I-II) | 2.077 (1.484-2.908) | <0.001 | 2.058 (1.457-2.906) | <0.001 |
| KRAS (wild type vs. mutant) | 1.125 (0.812-1.558) | 0.479 | ||
| BRAF (wild type vs. mutant) | 0.842 (0.552-1.285) | 0.425 | ||
| TP53 (wild type vs. mutant) | 0.65 (0.456-0.927) | 0.017 | 0.774 (0.536-1.119) | 0.173 |
| ATP8B1 expression (low vs. high) | 1.743 (1.247-2.435) | 0.001 | 1.512 (1.069-2.137) | 0.019 |
| TCGA CRC/PFI (n = 359) | ||||
| Gender (male vs. female) | 1.292 (0.97-1.722) | 0.08 | ||
| Age (≤65 vs. >65) | 1.168 (0.884-1.542) | 0.275 | ||
| Stage (III-IV vs. I-II) | 2.132 (1.587-2.864) | <0.001 | 2.029 (1.509-2.729) | <0.001 |
| KRAS (wild type vs. mutant) | 0.873 (0.66-1.154) | 0.339 | ||
| BRAF (wild type vs. mutant) | 1.315 (0.828-2.087) | 0.246 | ||
| TP53 (wild type vs. mutant) | 0.798 (0.595-1.07) | 0.131 | ||
| ATP8B1 expression (low vs. high) | 1.739 (1.298-2.331) | <0.001 | 1.62 (1.207-2.174) | 0.001 |
aCohorts were calculated using the Cox proportional hazards regression model. Bold indicates statistically significant values. bMultivariate analysis used the covariates associated with survival in univariate models (P < 0.05). The Wald statistic was applied to test whether the covariates were independent variables (P < 0.05). Bold indicates statistically significant values.